Products - Ear, nose and throat conditions | Topic | NICE

Showing 8 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 February 2026
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) (TA1123)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 January 2026
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 August 2025
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 March 2025
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2022
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 August 2021
Published:
26 March 2008
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2019